Nivagen Pharmaceuticals

Sacramento, United States Founded: 2009 • Age: 17 yrs Acquired By Pharmaceutical Associates
Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution

About Nivagen Pharmaceuticals

Nivagen Pharmaceuticals is a Healthcare company based in Sacramento (United States) founded in 2009, and was acquired by Pharmaceutical Associates in January 2026. Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution. Nivagen Pharmaceuticals has raised $30.97 million across 5 funding rounds from investors including Pharmaceutical Associates, BizCap and Telegraph Hill Partners. The company has 33 employees. Its chief executive, as recorded, is Jay Shukla. Its Indian entity Nivagen Pharma (India) Private Limited reported revenue of β‚Ή11.21 Cr. Nivagen Pharmaceuticals offers products and services including CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.

Company details

Nivagen Pharmaceuticals was founded in 2009 and is based in Sacramento, United States. Operations focus on the pharmaceutical sector, where generic drugs are developed and manufactured through contract services. Tablets, capsules, ointments, and solutions form the core product range. The company supports generic drug production for various clients in the healthcare industry.

Key Metrics
  • Indian entity revenue
    ₹11.21 Cr

    FY 2024 · +21% YoY

  • Indian entity net profit
    ₹1.30 Cr

    FY 2024 · 12% margin

  • Indian entity EBITDA
    ₹1.82 Cr

    FY 2024 · 16% margin

  • Total Equity Funding
    $30.97M (USD)

    in 5 rounds

  • Latest Funding Round
    $5M (USD), Series B

    Aug 2023

  • Investors
  • Employee Count
    33
  • Acquired by

Products & Services of Nivagen Pharmaceuticals

Nivagen Pharmaceuticals offers a comprehensive portfolio of products and services, including CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products.

CDMO Services
Contract Manufacturing

Offers drug development and manufacturing for partners.

Generic Prescription Drugs
Pharmaceuticals

Develops and markets affordable generic drugs for North America.

Specialty Drugs
Pharmaceuticals

Produces sterile injectables and formulations for institutional use.

Over-the-Counter Products
Consumer Health

Markets non-prescription drugs for everyday consumer needs.

Funding Insights of Nivagen Pharmaceuticals

Nivagen Pharmaceuticals has successfully raised a total of $30.97M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $30.97M
  • Total Rounds 5
  • Last Round Series B β€” $5M
  • First Round $10M

    (Sep 2017)

  • Investors Count 2

All 5 funding rounds of Nivagen Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2023$5MSeries B––
–
Sep 2022$45MDebt – Conventional––
May 2020$15.97MSeries B–Telegraph Hill Partners
–
Mar 2020$8MDebt – Conventional––
Sep 2017$10MSeries A––
–
Valuation history

3 investors in total: 3 institutional.

Investors in Nivagen Pharmaceuticals

Nivagen Pharmaceuticals has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Pharmaceutical Associates, BizCap and Telegraph Hill Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on life science, medical device and healthcare companies
thpartners.netSan Francisco, United States
Small & middle market focused investment bank
2002bizcap.comSan Francisco, United States
Generic liquid drugs are manufactured by Pharmaceutical Associates.
1968paipharma.comGreenville, United States
Premium access

Investor details for Nivagen Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Nivagen Pharma (India) Private Limited (Nivagen Pharmaceuticals)

Nivagen Pharma (India) Private Limited is the primary company behind Nivagen Pharmaceuticals. The board of Nivagen Pharma (India) Private Limited currently have 2 directors; the longest-serving is Jwalant Shukla, appointed in 2018. 2 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jwalant Shukla
DIN 08249559
Director05 Oct 20188 yrs 1 moNivagen Pharma (India) Private Limited
Parthil Paragbhai Shukal
DIN 11466101
Director16 Jan 202610 moNivagen Pharma (India) Private Limited

People of Nivagen Pharmaceuticals

24 people are tracked at Nivagen Pharmaceuticals (6 in leadership, 18 in team); the tracked headcount is 33.

NameRoleGroup
Jay Shukla
CEO & PresidentLeadership
Siddharth Mate
General ManagerLeadership
Gopal S. Patel
Vice President Global Regulatory AffairsLeadership
Vishal Narang Ph.d.
Sr.general Manager, Clinical Drug DevelopmentLeadership
Nirav Patel
Vice President Research And DevelopmentLeadership
Rob Hart
DirectorLeadership
Meet Kanojia
Quality Assurance ChemistTeam
Brijesh Pandya
Senior ChemistTeam
Gautam Gaitonde
Product Development ScientistTeam
Priyank Patel
Agm- Project ManagementTeam
Niravkumar Prajapati
PharmaceuticalTeam
Meenakshi Shripat Acharya
Regulatiry Affairs ScientistTeam
Devendra Patel
Regulatory Affairs ExecutiveTeam
Miten Vyasa
Sr. Executive - Regulatory AffairsTeam
Punit P.
Manager - Business DevelopmentTeam
Govind Jagadale
Sr. ChemistTeam
Nidhi Patel
AssistantTeam
Kailash Rawat
AGM - Global API Sourcing & ProcurementTeam
Jaydeep Patel
Supply Chain ManagementTeam
Ronak Gandhi
Sr. ExecutiveTeam

4 more people are available in the full profile.

Premium access

Complete people profiles for Nivagen Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Nivagen Pharmaceuticals

Figures of Nivagen Pharma (India) Private Limited, the primary company behind Nivagen Pharmaceuticals, for FY 2024. Revenue was ₹11.21 Cr (+21% year on year). Net profit was ₹1.30 Cr (12% margin). EBITDA was ₹1.82 Cr (16% margin). Revenue has grown at a compounded annual rate of +36% over three years and +104% over five years.

  • ₹11.21 CrRevenue · FY 2024 · +21% YoY
  • ₹1.30 CrNet profit · 12% margin
  • ₹1.82 CrEBITDA · 16% margin
  • ₹1 LakhPaid-up capital
  • 33Employees (provident fund records)
  • +36%Revenue CAGR, 3 years
  • +104%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Nivagen Pharma (India) Private Limited are on its company page.

Premium access

Detailed financial statements for Nivagen Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Nivagen Pharmaceuticals

4 dated milestones of Nivagen Pharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nivagen Pharmaceuticals is founded.
  2. Funding First funding round of $10.0M.
  3. Funding Latest funding round, Series B, of $5.0M.
  4. Exit Acquired by Pharmaceutical Associates.

Web traffic of Nivagen Pharmaceuticals

The website of Nivagen Pharmaceuticals (nivagen.com) receives about 8.5K visits a month.

  • Monthly visits
    8.5K

    ▲ 54.2% vs previous month

Similar websites

Websites whose visitors overlap most with Nivagen Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cichlidresearch.com
cichlidresearch.com
100%
#14,672,194–
molecularmatrix.com
99%
1.5K#11,523,751View details
handbiolab.com
handbiolab.com
95%
#4,240,186–
geminibio.com
94%
7.9K#2,451,069View details
thermogenesis.com
88%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for Nivagen Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Nivagen Pharmaceuticals (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nivagen Pharmaceuticals

Premium access

Complete news archive for Nivagen Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nivagen Pharmaceuticals

Nivagen Pharmaceuticals was founded in 2009 and raised its 1st funding round 8 years after it was founded.

Nivagen Pharmaceuticals is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.

Jay Shukla is the CEO of Nivagen Pharmaceuticals, as recorded in our data.

Nivagen Pharmaceuticals is a funded company, having raised a total of $30.97M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Sep 2017.

Nivagen Pharmaceuticals has 33 employees.

The primary company behind Nivagen Pharmaceuticals, Nivagen Pharma (India) Private Limited, reported revenue of β‚Ή11.21 Cr for FY 2024, up 21% year on year.

Nivagen Pharmaceuticals was founded in 2009 and is based in Sacramento, United States. Operations focus on the pharmaceutical sector, where generic drugs are developed and manufactured through contract services. Tablets, capsules, ointments, and solutions form the core product range. The company supports generic drug production for various clients in the healthcare industry.

Nivagen Pharmaceuticals offers CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products.

Nivagen Pharmaceuticals has 3 investors. Key investors include Pharmaceutical Associates, BizCap, and Telegraph Hill Partners.

Nivagen Pharmaceuticals operates through Nivagen Pharma (India) Private Limited.

Yes. Nivagen Pharmaceuticals was acquired by Pharmaceutical Associates in January 2026.

The legal entities of Nivagen Pharmaceuticals currently have 2 directors, including Jwalant Shukla, Parthil Paragbhai Shukal.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available